S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:NEXI

NexImmune (NEXI) Stock Price, News & Analysis

$5.51
-0.18 (-3.16%)
(As of 03/27/2024 ET)
Today's Range
$5.51
$5.75
50-Day Range
$5.00
$15.19
52-Week Range
$1.25
$28.69
Volume
17,565 shs
Average Volume
99,102 shs
Market Capitalization
$5.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NEXI stock logo

About NexImmune Stock (NASDAQ:NEXI)

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

NEXI Stock Price History

NEXI Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
NexImmune slips after securities offering
NexImmune, Inc. Common Stock (NEXI)
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Why Is NexImmune (NEXI) Stock Up 353% Today?
NexImmune Inc Ordinary Shares NEXI
NexImmune Announces 1-for-25 Reverse Stock Split
NexImmune announces 53% reduction in workforce
See More Headlines
Receive NEXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NEXI
Fax
N/A
Employees
22
Year Founded
N/A

Profitability

Net Income
$-62,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$33.43 per share

Miscellaneous

Free Float
853,000
Market Cap
$5.84 million
Optionable
Not Optionable
Beta
1.90
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Ms. Kristi Jones R.Ph. (Age 61)
    CEO, President & Director
    Comp: $680.44k
  • Dr. Mathias Oelke Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $621.26k
  • Mr. John Trainer M.B.A. (Age 50)
    Consultant
    Comp: $546.13k
  • Dr. Jerome Bernard Zeldis M.D. (Age 74)
    Ph.D., Consultant
    Comp: $618.2k
  • Mr. Timothy Stover
    VP, Corporate Controller and Principal Financial & Accounting Officer
  • Mr. Karen Haslbeck
    Head of Human Resources
  • Dr. Daniel P. Bednarik
    Senior Vice President of Molecular Engineering & Protein Design
  • Dr. Robert Douglas Knight M.D. (Age 73)
    Chief Medical Officer
    Comp: $454.77k
  • Mr. Chad Rubin
    Senior Vice President of Corporate Affairs
  • Dr. Jack A. Ragheb M.D.
    Ph.D., Senior Vice President of Translational Science

NEXI Stock Analysis - Frequently Asked Questions

How have NEXI shares performed in 2024?

NexImmune's stock was trading at $2.22 at the start of the year. Since then, NEXI stock has increased by 148.2% and is now trading at $5.51.
View the best growth stocks for 2024 here
.

Are investors shorting NexImmune?

NexImmune saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 35,200 shares, an increase of 122.8% from the February 29th total of 15,800 shares. Based on an average trading volume of 2,120,000 shares, the short-interest ratio is presently 0.0 days. Approximately 4.5% of the shares of the stock are short sold.
View NexImmune's Short Interest
.

How were NexImmune's earnings last quarter?

NexImmune, Inc. (NASDAQ:NEXI) announced its quarterly earnings data on Friday, November, 12th. The company reported ($16.25) EPS for the quarter, beating the consensus estimate of ($16.75) by $0.50.

When did NexImmune's stock split?

NexImmune's stock reverse split on Thursday, October 19th 2023. The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did NexImmune IPO?

NexImmune (NEXI) raised $75 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 4,700,000 shares at $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. acted as the underwriters for the IPO.

Who are NexImmune's major shareholders?

NexImmune's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include PNC Financial Services Group Inc. (1.19%) and PNC Financial Services Group Inc. (1.19%). Insiders that own company stock include Alan S Roemer, Grant Verstandig, Kristi Jones and Sol J Barer.
View institutional ownership trends
.

How do I buy shares of NexImmune?

Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NEXI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners